Triple-class refractory MM patients have a poor outcome and have an unmet medical need for new effective therapies. The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients who receive standard-of-care therapies. The first analysis of this study showed that these triple-class exposed patients (74% triple-class refractory) had an overall response rate of only 20% with standard-of-care salvage therapies. This clearly indicates that we need new agents with novel mechanism of action for these patients. Promising in this respect are the different T-cell redirecting therapies that are currently under investigation in heavily pre-treated MM patients.
CAR T-cell therapy
